Finch Therapeutics Group Top Insiders
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Finch Therapeutics employs about 1 people. The company is managed by 11 executives with a total tenure of roughly 3 years, averaging almost 0.0 years of service per executive, having 0.09 employees per reported executive. Assessment of Finch Therapeutics' management performance can provide insight into the firm performance.
| MD MBA Insider Chief Officer |
| Lance CPA Executive Chief Officer |
Finch |
Finch Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2194) % which means that it has lost $0.2194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6264) %, meaning that it created substantial loss on money invested by shareholders. Finch Therapeutics' management efficiency ratios could be used to measure how well Finch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Finch Therapeutics Workforce Comparison
Finch Therapeutics Group is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 901. Finch Therapeutics adds roughly 1.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Finch Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Finch Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Finch Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Finch Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smisek Jeffery A over six months ago Disposition of 3750 shares by Smisek Jeffery A of Finch Therapeutics subject to Rule 16b-3 | ||
Graf Susan E over six months ago Acquisition by Graf Susan E of 44843 shares of Finch Therapeutics subject to Rule 16b-3 | ||
Smisek Jeffery A over six months ago Disposition of 6642 shares by Smisek Jeffery A of Finch Therapeutics at 2.57 subject to Rule 16b-3 | ||
Smisek Jeffery A over a year ago Sale by Smisek Jeffery A of 1470 shares of Finch Therapeutics | ||
Blischak Matthew P over a year ago Acquisition by Blischak Matthew P of 962899 shares of Finch Therapeutics subject to Rule 16b-3 | ||
Blaustein Marc over a year ago Sale by Blaustein Marc of 4619 shares of Finch Therapeutics |
Finch Therapeutics Notable Stakeholders
A Finch Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Finch Therapeutics often face trade-offs trying to please all of them. Finch Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Finch Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD MBA | Chief Officer | Profile | |
| Lance CPA | Chief Officer | Profile | |
| Bryan MBA | Chief Officer | Profile | |
| Sonia Timberlake | VP Research | Profile | |
| CFA CFA | Principal COO | Profile | |
| Mark Smith | CEO Director | Profile | |
| Alka Batycky | Chief Officer | Profile | |
| JD Esq | Chief Sec | Profile | |
| Matthew JD | Chief Officer | Profile | |
| James Sigler | Ex CMC | Profile | |
| James MBA | Executive CMC | Profile |
About Finch Therapeutics Management Performance
The success or failure of an entity such as Finch Therapeutics often depends on how effective the management is. Finch Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Finch management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Finch management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.
Finch Therapeutics Workforce Analysis
Traditionally, organizations such as Finch Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Finch Therapeutics within its industry.Finch Therapeutics Manpower Efficiency
Return on Finch Therapeutics Manpower
| Revenue Per Employee | 107K | |
| Revenue Per Executive | 9.7K | |
| Net Loss Per Employee | 74.8M | |
| Net Loss Per Executive | 6.8M | |
| Working Capital Per Employee | 21.8M | |
| Working Capital Per Executive | 2M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |